［1］ Li J,Yao H, Jin W ,et al. Pharmacokinetics of leflunomide in Chinese healthy volunteers ［J］.Acta Pharmacol Sin, 2002, 23(6):551-555.
［2］ Beaman J M, Hackett L P, Luxton G，et al.. Effect of hemodialysis on leflunomide plasma concentrations［J］. Ann Pharmacother, 2002, 36(1):75-77.
［3］ Iwamoto M, Homma S, Asano Y, et al. Administration of leflunomide to a patient with rheumatoid arthritis on haemodialysis［J］.Scand J Rheumatol,2005,34(5):410-411.
［4］ H M Cherwinski, N Byars, S J Ballaron，et al. Leflunomide interferes with pyrimidine nucleotide biosynthesis［J］.Inflamm Res,1995,44(8):317-322.
［5］ I González-Alvaro1, A M Ortiz1, C Domínguez-Jiménez1 ,et al. Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway［J］.Ann Rheum Dis, 2009,68(10):1644-1650.
［6］ M C Kraan, R J Reece, E C Barg,et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis（Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers）［J］.Arthritis Rheum,2000 ,43(8):1820-1830.
［7］ 王玉柱,周春华.来氟米特抑制结缔组织生长因子诱导的肾间质成纤维细胞增殖和胶原的合成的研究［J］.中国现代医学杂志，2008,17（13）：1545-1548.
［8］ Manna S K,Aggarwal B B. Immunosuppressive leflunomide metabolite (A771726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression［J］.J Immunol, 1999, 162(4):2095-2102.
［9］ Zeyda M, Kirsch B M, Geyeregger R.et al. Inhibition of Human Dendritic Cell Maturation and Function by the Novel Immunosuppressant FK778 ［J］.Transplant Proc,2005,80(8): 1105-1111.
［10］ Kirsch B M, Zeyda M, Stuhlmeier K,et al.The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function［J］. Arthritis Res Ther,2005,7(3):694-703.
［11］ Farasati N A, Shapiro R, Vats A. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system［J］.Transplantation， 2005,79: 116–117.
［12］ Lou T , Wang C, Chen Z， et al. Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy ［J］. Nephrology (Carlton), 2006 ,11(2):113-116.
［13］ 沈建松,李大林,朱向军，等.来氟米特、ACEI联合治疗IgAN的临床前瞻性对照研究［J］.中华全科医学，2010，8（10）：1217-1219.
［14］ Zhaohui Ni . Leflunomide plus low dose prednisone could reduce proteinuria and stabilize kidney founction in progressive IgA nephropathy at 2 year follow-up study，ASN 2008［J］. American Society of Nephrology，2008：P.Abstract Number:555361.
［15］ 傅 鹏，于 光，许 静，等.来氟米特联合激素延缓进展型IgA肾病肾功能减退的临床研究［J］.临床内科杂志，2006，23（11）：731-733.
［16］ Liu X W, Li D M, Xu G S， et al. Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin a nephropathy manifesting with nephrotic syndrome［J］.Int J Clin Pharmacol Ther,2010,48(8):509-513.
［17］ 毛瑞阳，张媛元，孙文学，等.来氟米特与雷公藤多苷及单纯激素治疗 IgA 肾病的疗效观察［J］.中国中西医结合肾病杂志，2009，10 (7 )：604-606.
［18］ 王一冰，张 磊，鹿 松，等.来氟米特与环磷酰胺治疗重症儿童IgA 肾病的疗效比较［J］.中国现代医生，2009, 47（10）：11-12.
［19］ Cui T G, Hou F F, Ni Z H, et al. Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial.B［J］.Zhonghua Nei Ke Za Zhi,2005,44(9):672-676.
［20］ 胡伟新，章海涛，孙海鸥，等.来氟米特维持治疗狼疮性肾炎的临床疗效［J］.肾脏病与透析肾移植杂志，2008，17（3）：224-228.
［21］ Tam L S, Li E K, Wong C K, et al. Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial［J］.Ann Rheum Dis,2006,65(3):417-418.
［22］ 任 琪，曾华松.来氟米特治疗狼疮性肾炎疗效和安全性的 Ｍeta分析［J］. 中国循证儿科杂志，2011,16(2):104-109.
［23］ 丛 敏，江 蓓，胡 昭，等.来氟米特治疗原发性难治性肾病综合征的多中心临床观察［J］.山东大学学报(医学版)，2007，45（3）：295-298.
［24］ Williams J W, Mital D, Chong A, et al.Experiences with leflunomide in solid organ transplantation ［J］.Transplantation ,2001,73(3):358-366.
［25］ Karen L， Hardinger, Candace D, et al. Prospective, Pilot, Open‐Label, Short‐Term Study of Conversion to Leflunomide Reverses Chronic Renal Allograft Dysfunction ［J］.Am J Transplant ,2002,2(9):867-871.
［26］ Williams J W, Javaid B, Kadambi PV, et al. Leflunomide for polyomavirus type BK nephropathy ［J］.N Engl J Med, 2005,352(11):1157-1158.
［27］ Ian C， Davis, Eduardo R, et al. Leflunomide Prevents Alveolar Fluid Clearance Inhibition by Respiratory Syncytial Virus［J］. American Journal of Respiratory and Critical Care Medicine,2006,173:673-682.
［28］ 孙 剑，张 浩，刘纪实，等.来氟米特与霉酚酸酯治疗表现为肾病综合征的过敏紫癜性肾炎的疗效比较［J］.中国中西医结合肾病杂志，2008，9（8）：691-693.
［29］ 付 宇，王 丹，石 鹏.来氟米来氟米特与环磷酰胺治疗 HSPN 效果比较特治疗糖尿病肾病大量蛋白尿 20例临床分析［J］.临床内科杂志，2007，24（7）：470-471.
［30］ Zhang WX, Zhou W, Zhang ZQ，et al. Interstitial lung diseases after leflunomide use in nephropathy: an analysis of reported cases in Chinese literature［J］. Nephrol Dial Transplant , 2011,26(4):1416-1420.